Brief: Hutchmed (China) Initiates Global Phase A Trial Of HMPL-A830 In Advanced Solid Tumors
28/09/2026 02:34
BRIEF-Hutchmed (China) Initiates Global Phase A Trial Of HMPL-A830 In Advanced Solid Tumors Sept 28 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
INITIATES GLOBAL PHASE A TRIAL OF HMPL-A830 IN ADVANCED SOLID TUMORS
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation